Fink K, Schlicker E, Göthert M
Institut für Pharmakologie und Toxikologie, Rheinischen Friedrich-Wilhelms-Universität Bonn, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):113-7. doi: 10.1007/BF00169826.
In superfused rat brain cortex slices and synaptosomes preincubated with [3H]noradrenaline the effect of agonists or antagonists at presynaptic H3 receptors on NMDA-evoked [3H]noradrenaline release was investigated. In experiments on slices, histamine and the preferential H3 receptor agonist R-(-)-alpha-methylhistamine inhibited NMDA-evoked tritium overflow (IC20 values 0.27 mumol/l or 0.032 mumol/l, respectively); S-(+)-alpha-methylhistamine (up to 10 mumol/l) as well as the selective H1 receptor agonist (2-(2-thiazolyl)ethylamine and the selective H2 receptor agonist dimaprit (each up to 10 mumol/l) were ineffective. The H3 receptor antagonist thioperamide abolished the inhibitory effect of histamine whereas the preferential H1 receptor antagonist dimetindene and the preferential H2 receptor antagonist ranitidine were ineffective. In experiments on synaptosomes, histamine and R-(-)-alpha-methylhistamine inhibited NMDA-evoked tritium overflow, whereas 2-(2-thiazolyl)ethylamine or dimaprit had no effect. The inhibitory effect of histamine was abolished by thioperamide. When tritium overflow was stimulated by NMDA in the presence of omega-conotoxin GVIA (which by itself decreased the response to NMDA by about 55%), R-(-)-alpha-methylhistamine did not inhibit NMDA-evoked overflow. It is concluded that NMDA-evoked noradrenaline release in the cerebral cortex can be modulated by inhibitory H3 receptors. NMDA receptors and H3 receptors are both located presynaptically and may interact at the same noradrenergic varicosity. An unimpaired function of the N-type voltage-sensitive calcium channel probably is a prerequisite for the inhibition of NMDA-evoked noradrenaline release by H3 receptor stimulation.
在用[3H]去甲肾上腺素预孵育的灌流大鼠脑皮质切片和突触体中,研究了突触前H3受体激动剂或拮抗剂对NMDA诱发的[3H]去甲肾上腺素释放的影响。在切片实验中,组胺和优先性H3受体激动剂R-(-)-α-甲基组胺抑制NMDA诱发的氚溢出(IC20值分别为0.27μmol/L或0.032μmol/L);S-(+)-α-甲基组胺(高达10μmol/L)以及选择性H1受体激动剂(2-(2-噻唑基)乙胺)和选择性H2受体激动剂二甲双胍(均高达10μmol/L)均无作用。H3受体拮抗剂硫代哌啶消除了组胺的抑制作用,而优先性H1受体拮抗剂二甲茚定和优先性H2受体拮抗剂雷尼替丁则无作用。在突触体实验中,组胺和R-(-)-α-甲基组胺抑制NMDA诱发的氚溢出,而2-(2-噻唑基)乙胺或二甲双胍则无作用。硫代哌啶消除了组胺的抑制作用。当在ω-芋螺毒素GVIA存在下用NMDA刺激氚溢出时(ω-芋螺毒素GVIA本身使对NMDA的反应降低约55%),R-(-)-α-甲基组胺不抑制NMDA诱发的溢出。结论是,大脑皮质中NMDA诱发的去甲肾上腺素释放可被抑制性H3受体调节。NMDA受体和H3受体均位于突触前,可能在同一去甲肾上腺素能曲张体处相互作用。N型电压敏感性钙通道功能正常可能是H3受体刺激抑制NMDA诱发的去甲肾上腺素释放的前提条件。